An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their ...

Boehringer Ingelheim, IP Group, UK Respiratory Gene Therapy Consortium, and OXB launched the first-in-human clinical trial, known as LENTICLAIR 1.

An inhalable medicine with the potential to improve lung disease in people with cystic fibrosis, irrespective of their ...

OXB announces that its proprietary lentiviral vector manufacturing technology will be used in Boehringer Ingelheim’s newly initiated LENTICLAIR ...

Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC) 1 and OXB, 1 today announce the start of LENTICLAIR TM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, ...

With a market cap of $118.7 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology leader specializing ...

Researchers at Imperial College London are leading human trials for the innovative treatmentAn inhalable medicine with the potential to improve lung ...

NARBERTH, Pennsylvania (WPVI) -- "Take A Breather Foundation" based in Narberth is a stress relief outlet for people with cystic fibrosis. Their focus is to provide a "breather" to their recipients, ...

The global Cystic Fibrosis Market is valued at $10.4 billion in 2023 and is projected to reach $55.4 billion by 2032, ...

Castle Rock Cafe & Mercantile near Laguna Seca Raceway is holding a special promo in support of local health agency during ...

A research team co-led by scientists at the University of Arizona College of Medicine—Tucson found that an osteoporosis drug ...